Patents
More topics under "C07D - Heterocyclic compounds" (1,537,440)
C07D 201 - Preparation, separation, purification, or stabilisation of unsubstituted lactams (2,192)
C07D 203 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom (1,097)
C07D 205 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom (6,868)
C07D 207 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom (40,304)
C07D 209 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom (45,780)
C07D 211 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings (37,939)
C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members (63,273)
C07D 215 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems (27,676)
C07D 217 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems (11,865)
C07D 219 - Heterocyclic compounds containing acridine or hydrogenated acridine ring systems (2,120)
C07D 221 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups (10,931)
C07D 223 - Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom (8,732)
C07D 225 - Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom (1,649)
C07D 227 - Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups (473)
C07D 229 - Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms (515)
C07D 231 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings (25,550)
C07D 233 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings (34,408)
C07D 235 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings (15,325)
C07D 237 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings (8,468)
C07D 239 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings (42,619)
C07D 241 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings (18,673)
C07D 243 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms (5,961)
C07D 245 - Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms (898)
C07D 247 - Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups (239)
C07D 249 - Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms (17,749)
C07D 251 - Heterocyclic compounds containing 1,3,5-triazine rings (10,913)
C07D 253 - Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group (2,967)
C07D 255 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups (739)
C07D 257 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms (9,612)
C07D 259 - Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms (488)
C07D 261 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings (11,459)
C07D 263 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings (20,978)
C07D 265 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms (11,132)
C07D 267 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms (2,022)
C07D 269 - Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups (111)
C07D 271 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms (7,144)
C07D 273 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups (2,368)
C07D 275 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings (4,972)
C07D 277 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings (33,621)
C07D 279 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms (5,149)
C07D 281 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms (1,924)
C07D 283 - Heterocyclic compounds containing rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms, according to more than one of groups (102)
C07D 285 - Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups (9,964)
C07D 291 - Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms (1,087)
C07D 293 - Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms (553)
C07D 295 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms (34,005)
C07D 301 - Preparation of oxiranes (10,136)
C07D 303 - Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom (12,512)
C07D 305 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms (5,442)
C07D 307 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom (47,108)
C07D 309 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings (12,815)
C07D 311 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings (24,127)
C07D 313 - Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom (3,580)
C07D 315 - Heterocyclic compounds containing rings having one oxygen atom as the only ring hetero atom according to more than one of groups (1,360)
C07D 317 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms (18,224)
C07D 319 - Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms (10,283)
C07D 321 - Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups (2,079)
C07D 323 - Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms (1,581)
C07D 325 - Heterocyclic compounds containing rings having oxygen as the only ring hetero atom according to more than one of groups (168)
C07D 327 - Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms (2,428)
C07D 329 - Heterocyclic compounds containing rings having oxygen and selenium or oxygen and tellurium atoms as the only ring hetero atoms (47)
C07D 331 - Heterocyclic compounds containing rings of less than five members, having one sulfur atom as the only ring hetero atom (456)
C07D 333 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom (32,883)
C07D 335 - Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom (4,725)
C07D 337 - Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom (875)
C07D 339 - Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms (3,352)
C07D 341 - Heterocyclic compounds containing rings having three or more sulfur atoms as the only ring hetero atoms (281)
C07D 343 - Heterocyclic compounds containing rings having sulfur and selenium or sulfur and tellurium atoms as the only ring hetero atoms (52)
C07D 345 - Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms (419)
C07D 347 - Heterocyclic compounds containing rings having halogen atoms as ring hetero atoms (38)
C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group (62,587)
C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom (69,397)
C07D 407 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group (11,963)
C07D 409 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms (52,226)
C07D 411 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms (2,465)
C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
C07D 415 - Heterocyclic compounds containing the thiamine skeleton (90)
C07D 417 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group (62,773)
C07D 419 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms (1,431)
C07D 421 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms (480)
C07D 451 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof (5,273)
C07D 453 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids (5,704)
C07D 455 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine (2,122)
C07D 457 - Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula: , e.g. lysergic acid (836)
C07D 459 - Heterocyclic compounds containing benz [g] indolo [2, 3-a] quinolizine ring systems, e.g. yohimbine; 16, 18-lactones thereof, e.g. reserpic acid lactone (97)
C07D 461 - Heterocyclic compounds containing indolo [3, 2, 1-d, e] pyrido [3, 2, 1-i, j] [1, 5]-naphthyridine ring systems, e.g. vincamine (286)
C07D 463 - Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (613)
C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups (64,559)
C07D 473 - Heterocyclic compounds containing purine ring systems (11,932)
C07D 475 - Heterocyclic compounds containing pteridine ring systems (2,718)
C07D 477 - Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (2,484)
C07D 487 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups (57,272)
C07D 489 - Heterocyclic compounds containing 4ah-8, 9 c- iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: (2,334)
C07D 491 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or (29,726)
C07D 493 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system (17,376)
C07D 495 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms (21,336)
C07D 497 - Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms (1,069)
C07D 498 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms (21,960)
C07D 499 - Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (3,448)
C07D 501 - Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (7,574)
C07D 503 - Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (648)
C07D 505 - Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (556)
C07D 507 - Heterocyclic compounds containing a condensed beta-lactam ring system, not provided for by groups , or; Such ring systems being further condensed (161)
C07D 513 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (15,120)
C07D 515 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (877)
C07D 517 - Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms (452)
C07D 519 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or (11,041)
C07D 521 - Heterocyclic compounds containing unspecified hetero rings (16,203)
Patents for C07D - Heterocyclic compounds (10,420)
09/2004
09/02/2004CA2516250A1 A1 adenosine receptor antagonists
09/02/2004CA2511979A1 Halogenated oxime derivatives and the use thereof as latent acids
09/01/2004EP1450792A1 Benzazole derivatives for the treatment of scleroderma
09/01/2004EP1292594B1 Quinazoline derivatives for the treatment of tumours
09/01/2004EP1165528B1 Novel morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives
09/01/2004CN1524852A Novel compounds with analgesic effect
08/2004
08/31/2004US6784292 Method for the production of imidazo-(1,2-C)(2,3)-benzodiazepines and intermediates in the production thereof
08/31/2004US6784198 Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents
08/26/2004WO2004072033A2 Pyrazoles and methods of making and using the same
08/26/2004WO2004072030A2 Process for preparing pyrrolotriazine kinase inhibitors
08/26/2004WO2004072029A2 Pyrazolopyridazines useful as inhibitors of protein kinases
08/26/2004WO2004072024A2 Polyisobutene phosphonic acid and the derivatives thereof
08/26/2004WO2004072023A2 Oxathiin carboxamide
08/26/2004WO2004000800A3 Electrochromic salts, solutions, and devices
08/26/2004US20040167210 Crystalline base of citalopram
08/26/2004US20040167141 Anticancer agents; antidiabetic agents; Alzheimer's disease
08/26/2004US20040166137 Prevention membrane fusion, transmission of virus; respiratory syncytial virus
08/26/2004CA2515922A1 Oxathiin carboxamide
08/26/2004CA2515218A1 Process for preparing pyrrolotriazine kinase inhibitors
08/26/2004CA2514382A1 Pyrazoles and methods of making and using the same
08/25/2004EP1449842A1 Process for the preparation of pyrazolopyridine tartrates
08/25/2004EP1448566A2 Chemokine receptor antagonists and methods of use thereof
08/25/2004EP1448524A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
08/25/2004EP1448523A1 Heterocyclic compounds and methods of use
08/25/2004EP1448201A2 Use of n-(indolcarbonyl-)piperazine derivatives
08/25/2004CN1163492C 'Delta' 12,13-iso-taxol analogs, antineoplastic use and pharmaceutical composition containing them
08/25/2004CN1163491C 3-amino-2-mercapto benzoic acid derivative and its preparation method
08/25/2004CN1163488C Process for preparing insecticide
08/24/2004US6780879 As antitumor agent
08/24/2004US6780876 Composition for keeping away vermin
08/24/2004CA2285733C Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof
08/19/2004WO2004069795A2 Diagnosis and treatment of chronic tissue damage
08/19/2004WO2004069794A2 New arylpiperazinyl compounds
08/19/2004WO2004069793A2 Novel 2-substituted cyclic amines as calcium sensing receptor modulators
08/19/2004WO2004069790A2 Crystalline modifications of triazinylaminostilbenes
08/19/2004US20040162410 Thrombosis therapy; anticoagulants
08/19/2004DE10305623A1 Polyisobutene phosphonic acids are useful as a surface modifier for organic or inorganic materials, as a corrosion inhibitor, antiwear agent, emulsifier, dispersing agent, adhesion promoter, wetting agent or printing ink additive
08/19/2004CA2513915A1 New arylpiperazinyl compounds
08/18/2004EP1446401A2 C-5 modified indazolylpyrrolotriazines
08/18/2004EP1446123A1 Rosuvastatin in pre demented states
08/18/2004EP1446122A1 Use of flibanserin in the treatment of sexual disorders
08/18/2004EP1222173B1 Process for preparing 4-trifluoromethylsulphinylpyrazole derivative
08/18/2004CN1522245A Substituted sulfonamide compounds, process for their use as medicament for the treatment of CNS disorders, obestity and type II diabetes
08/18/2004CN1521166A Process for preparing 1 -(3 -hydroxymethyl pyridyl-2) -2-phenyl-4- methyl piperazine
08/17/2004US6777555 3-(optionally hydroxyl)-4-(cyclopropylcarbonyl)-cumene intermediate
08/17/2004US6777406 Substituted pyrroloquinolines and pyridoquinolines as serotinin agonists and antagonists
08/12/2004WO2004067508A2 Use of photodynamic therapy therapeutic agents entrapped in ceramic nanoparticles
08/12/2004WO2004067506A2 Substituted heterocyclic compounds
08/12/2004WO2004067505A2 Bismuth dithiocarbamate compounds and uses thereof
08/12/2004WO2004054969A3 Sacromastigophoric therapeutic agent delivery system
08/12/2004US20040157893 Pyrazole compounds useful as protein kinase inhibitors
08/12/2004US20040157886 Brain disorders; central nervous system disorders; viricides
08/12/2004US20040157846 Process for preparing pyrrolotriazine kinase inhibitors
08/12/2004CA2513759A1 Ceramic based nanoparticles for entrapping therapeutic agents for photodynamic therapy and method of using same
08/12/2004CA2513641A1 Substituted heterocyclic compounds
08/11/2004EP1443932A1 Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
08/11/2004EP1140918B1 Thrombin inhibitors
08/11/2004EP1135381B1 Eletriptan hydrobromide monohydrate
08/11/2004CN1520405A Process for prepn. of racemic citalopram and/or S-or R-citalopram by separation of mixture of R-and S-citalopram
08/11/2004CN1520403A Novel polymorph v of torasemide
08/11/2004CN1161351C Novel form of S-omeprazole
08/11/2004CN1161331C Hydrazine derivatives
08/11/2004CN1161018C Composition for keeping away vermin
08/10/2004CA2293011C Process for the preparation of n-(amino-4,6-dihalopyrimidine)formamides
08/10/2004CA2187879C Dimethylfurancarboxyanilide derivative
08/05/2004WO2004065393A1 Novel compounds
08/05/2004WO2004065363A2 Computational design of a water-soluble analog of a protein, such as phospholamban and potassium channel kcsa
08/05/2004WO2003087054A3 Methods for identifying compounds that modulate enzymatic activity
08/05/2004CA2517848A1 Computational design of a water-soluble analog of a protein, such as phospholamban and potassium channel kcsa
08/05/2004CA2512736A1 Novel compounds
08/04/2004EP1317455B1 Process for preparing a substituted imidazopyridine compound
08/04/2004CN1518543A Pyrazole derivatives and their use as protein kinase inhibitors
08/04/2004CN1518542A Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
08/04/2004CN1160333C Ester of pipperidinemethanol and their use as prodrugs of the 5HT2A receptor antagonist MDL 110,907
08/04/2004CN1160081C Combination therapy of HIV infection using HIV protease inhibitior induinavir and reverse transcriptase inhibitor 3TC, optionally together with AZT, DDI or DDC
07/2004
07/29/2004WO2004063202A1 Fused furan compound
07/29/2004WO2004063157A1 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
07/29/2004WO2004063154A2 Environmentally benign anti-icing or deicing fluids
07/29/2004WO2004063150A2 Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process
07/29/2004WO2004062662A1 Aminoindazole derivatives and use thereof as kinase inhibitors
07/29/2004WO2004062562A2 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
07/29/2004WO2004041777A3 Heteroarylpiperidine modulators of chemokine receptor activity
07/29/2004WO2004033423A3 Anticancer compounds
07/29/2004US20040147538 Fused heterocyclic compounds
07/29/2004US20040147512 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
07/29/2004US20040147508 Biologically active methylene blue derivatives
07/29/2004US20040146542 Non-therapeutical process for deterring vermin from warm-blooded animals, whereby 2-substituted-piperidine compound is is applied topically, together with a spreading additive, to the skin, the pelt or the plumage of the warm-blooded animal
07/29/2004US20040146438 Method for recovery of metals from metal-containing materials using medium temperature pressure leaching
07/29/2004CA2512761A1 Environmentally benign anti-icing or deicing fluids
07/29/2004CA2510400A1 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
07/29/2004CA2510382A1 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
07/29/2004CA2507948A1 Aminoindazole derivates and use thereof as kinase inhibitors
07/28/2004EP1439836A1 Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome
07/28/2004EP0823895B1 Fatty acid esters as bioactive compounds
07/28/2004CN1516587A Quinazoline derivatives capable of promoting release of parathyroid
07/28/2004CN1516585A Process for preparing paroxetine HCI which limits formation of pink colored compounds
07/28/2004CN1515570A Preparation method of pyrazolo [4,3-C] pyridine-3-ketone L-tartate
07/28/2004CN1515562A Phenyl-and aminophenyl-alkyl sulfonamide and urea derivative
07/28/2004CN1515559A Phenyl-and aminophenyl-alkyl sulfonamide and urea derivative
07/28/2004CN1515317A Combined therapeutic method for osteoporosis
1 ... 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 ... 105